Drugs / LAE102
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07230496 | Dec 2025 → Mar 2028 expected | — | Laekna Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT06908707 | Apr → Oct 2025 | — | Laekna Limited | Completed | No outcome recorded |
| Phase 1 | NCT06493084 | Jun 2024 → Sep 2026 expected | — | Laekna Limited | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07671391 | Aug 2026 → Jul 2027 expected | — | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAE102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07230496 ↗ |
| Route | Intravenous | “administered intravenously” NCT06493084 ↗ |